278 related articles for article (PubMed ID: 25877052)
1. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice.
Carruthers RL; Berger J
Mult Scler Relat Disord; 2014 Jul; 3(4):419-30. PubMed ID: 25877052
[TBL] [Abstract][Full Text] [Related]
2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
3. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
[TBL] [Abstract][Full Text] [Related]
8. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
9. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
10. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab-related progressive multifocal leukoencephalopathy in Greece.
Mitsikostas DD; Mastorodemos V; Tsagournizakis M; Kodounis A; Tsagkaropoulos A; Konitsiotis S; Toulas P; Papadimitriou A; Papadimitriou D; Tavernarakis A; Papadopoulos D
Mult Scler Relat Disord; 2014 Mar; 3(2):203-10. PubMed ID: 25878008
[TBL] [Abstract][Full Text] [Related]
12. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
14. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
16. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
19. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
20. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]